Cold activation of complement in sera from patients with persistent hepatitis C virus infection on interferon therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 11, Issue 4, 1996, Pages 341-346

  Aikawa, T ^a   Kimura, I ^a   Kojima, M ^a   Ueno, C ^a   Miyamoto, K ^a   Tango, T ^a   Tanaka, N ^a  

^a Aikawa Internal Hospital   (Japan)

Author keywords

complement; cryoglobulins; hepatitis B; hepatitis B virus; hepatitis C; hepatitis C virus; interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; CRYOGLOBULIN; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; COLD; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; VIREMIA;

EID: 0029943736     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1996.tb01381.x     Document Type: Article

References (23)

1. 1 Dienstag JL, Bhan AK, Alter HJ, Feinstone SM, Purcell RH. Circulating immune complexes in non‐A, non‐B hepatitis. Possible masking of viral antigen. Lancet 1979 ; 1: 1265–7.
2. 2 Choo QL, Kuo G., Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood‐borne non‐A, non‐B viral hepatitis genome. Science 1989 ; 244: 359–62.
3. 3 Hijikata M., Shimizu YK, Kato H. et al. Equilibrium centrifugation studies of hepatitis C virus: Evidence for circulating immune complexes. J. Virol. 1993 ; 67: 1953–8.
4. 4 Ferri C., Greco F., Longombardo G. et al. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum. 1991 ; 34: 1606–10.
5. 5 Agnello V., Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N. Engl. J. Med. 1992 ; 327: 1490–5.
6. 6 Johnson RJ, Gretch DR, Yamabe H. et al. Membrano‐proliferative glomerulonephritis associated with hepatitis C virus infection. N. Engl. J. Med. 1993 ; 328: 465–70.
7. 7 Kitamura H., Nagaki K., Inoshita K., Iida K., Inai S. The cold activation of the classical complement pathway: The cause of the differences between plasma and serum complement in liver cirrhosis. Clin. Exp. Immunol. 1977 ; 27: 34–7.
8. 8 Ueda K., Nakajima H., Nakagawa T., Shimizu A. The association between hepatitis C virus infection and in vitro activation of the complement system. Ann. Clin. Biochem. 1993 ; 30: 565–9.
9. 9 Itoh K., Tanaka H., Shiga J. et al. Hypocomplementemia associated with hepatitis C viremia in sera from voluntary blood donors. Am. J. Gastroenterol. 1994 ; 89: 2019–24.
10. 10 Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non‐A, non‐B hepatitis with recombinant human alpha interferon. A preliminary report. N. Engl. J. Med. 1986 ; 315: 1575–8.
11. 11 Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N. Engl. J. Med. 1989 ; 321: 1501–6.
12. 12 Di Bisceglie AM, Martin P., Kassianides C. et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double‐blind, placebo‐controlled trial. N. Engl. J Med. 1989 ; 321: 1506–10.
13. 13 Tine F., Magrin S., Craxi A., Pagliaro L. Interferon for non‐A, non‐B chronic hepatitis. A meta‐analysis of randomised clinical trials. J. Hepatol 1991 ; 13: 192–9.
14. 14 Chayama K., Saitoh S., Arase Y. et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991 ; 13: 1040–3.
15. 15 Shindo M., DI BA, Cheung L. et al. Decrease in serum hepatitis C viral RNA during alpha‐interferon therapy for chronic hepatitis. C. Ann. Intern. Med. 1991 ; 115: 700–4.
16. 16 Hino K., Sainokami S., Shimoda K. et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J. Med. Virol. 1994 ; 42: 299–305.
17. 17 Okamoto H., Munekata E., Tsuda F. et al. Enzyme‐linked immunosorbent assay for antibodies against the capsid protein of hepatitis C virus with a synthetic oligopeptide. Jpn J. Exp. Med. 1990 ; 60: 223–33.
18. 18 Nagayama R., Miyake K., Tsuda F., Okamoto H. IgM antibody to hepatitis C virus core peptide (CP14) for monitoring activity of liver disease in patients with acute or chronic hepatitis C. J. Med. Virol. 1994 ; 42: 311–17.
19. 19 Okamoto H., Okada S., Sugiyama Y. et al. Detection of hepatitis C virus RNA by a two‐stage polymerase chain reaction with two pairs of primers deduced from the 5′‐noncoding region. Jpn. J. Exp. Med. 1990 ; 60: 215–22.
20. 20 Mayer MM. Complement and complement fixation. In: Kabat EA, Mayer MM, eds. Kabat and Mayer's Experimental Immunochemistry. Illinois: Charles C. Thomas, 1961 ; 133–240.
21. 21 Inai S., Kitamura H., Fujita T., Kojima J., Nagaki K. Differences between plasma and serum complement in patients with chronic liver disease. Clin. Exp. Immunol. 1976 ; 25: 403–9.
22. 22 Linscott WD, Kane JP. The complement system in cryoglobulinaemia. Interaction with immunoglobulins and lipoproteins. Clin. Exp. Immunol. 1975 ; 21: 510–19.
23. 23 Lunel F., Musset L., Cacoub P. et al. Cryoglobulinemia in chronic liver diseases: Role of hepatitis C virus and liver damage. Gastroenterology 1994 ; 106: 1291–300.